E-viri
PDF
Recenzirano
Odprti dostop
-
Pemmaraju, Naveen; Lane, Andrew A; Sweet, Kendra L; Stein, Anthony S; Vasu, Sumithira; Blum, William; Rizzieri, David A; Wang, Eunice S; Duvic, Madeleine; Sloan, J. Mark; Spence, Sharon; Shemesh, Shay; Brooks, Christopher L; Balser, John; Bergstein, Ivan; Lancet, Jeffrey E; Kantarjian, Hagop M; Konopleva, Marina
The New England journal of medicine, 04/2019, Letnik: 380, Številka: 17Journal Article
Patients with blastic plasmacytoid dendritic-cell neoplasm, an aggressive hematologic cancer, were treated with the cytotoxin tagraxofusp in a dose-escalation case series. Previously untreated patients had a 72% complete response rate, and 45% underwent stem-cell transplantation. Toxic effects included hepatic dysfunction, thrombocytopenia, and capillary leak syndrome.
